Kandarakis Stylianos A, Togka Konstantina A, Doumazos Leonidas, Mylona Ioanna, Katsimpris Andreas, Petrou Petros, Kymionis George
First Department of Ophthalmology, G. Gennimatas Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Ophthalmology, General Hospital of Katerini, Katerini, Greece.
Ophthalmol Ther. 2023 Jun;12(3):1457-1478. doi: 10.1007/s40123-023-00699-9. Epub 2023 Mar 17.
Corneal endothelium is a single cell layer that is mainly responsible for maintaining corneal clarity. Endothelial damage secondary to toxicity, stress, or genetic predisposition are common and in conjunction with the low regenerative ability of the cells, making their preservation critical for maintaining visual acuity. Patients with glaucoma, who are estimated to be close to 80 million worldwide, have a plethora of reasons for developing endothelial damage, being exposed to a spectrum that extends from various medical and surgical interventions to the disease itself. The wide spectrum of glaucoma pharmacotherapy that has been recently extended by addition of newer classes of medications has been the focus of extensive research on its effects on corneal endothelium. Both basic and clinical research have attempted to shine a light on the complex mechanisms associated with the effects of glaucoma medication on corneal endothelium and to answer the important question as to whether these findings are clinically significant. The aim of this review is to summarize and present current literature of the various findings, both from in vivo and in vitro studies that have focused on the complex relationship between different classes of glaucoma medication and their effect on corneal endothelium.
角膜内皮是一层单细胞层,主要负责维持角膜的透明度。由毒性、压力或遗传易感性引起的内皮损伤很常见,再加上细胞的低再生能力,因此保护它们对于维持视力至关重要。全球估计有近8000万青光眼患者,他们有多种导致内皮损伤的原因,涉及从各种药物和手术干预到疾病本身的一系列因素。最近通过添加新型药物而扩大的广泛的青光眼药物治疗范围,一直是其对角膜内皮影响的广泛研究焦点。基础研究和临床研究都试图阐明与青光眼药物对角膜内皮影响相关的复杂机制,并回答这些发现是否具有临床意义这一重要问题。本综述的目的是总结并呈现当前文献中关于各种研究结果,这些结果来自体内和体外研究,这些研究聚焦于不同类别的青光眼药物与其对角膜内皮影响之间的复杂关系。